{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:02:11Z","timestamp":1789239731151,"version":"build-2803163510"},"reference-count":184,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s40263-021-00883-0","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T09:02:48Z","timestamp":1641805368000},"page":"143-165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Pharmacological Management of Apathy in Dementia"],"prefix":"10.1007","volume":"36","author":[{"given":"Laiba","family":"Azhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael W.","family":"Kusumo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Marotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista L.","family":"Lanct\u00f4t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9955-3155","authenticated-orcid":false,"given":"Nathan","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"issue":"4","key":"883_CR1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1177\/1715163515588107","volume":"148","author":"F Chang","year":"2015","unstructured":"Chang F, Patel T, Schulz ME. The \u201cRising Tide\u201d of dementia in Canada: what does it mean for pharmacists and the people they care for? Can Pharm J (Ott). 2015;148(4):193\u20139.","journal-title":"Can Pharm J (Ott)."},{"key":"883_CR2","unstructured":"Prince M, Wimo A, Guerchet M, Ali G-C, Wu Y-T, Prina M. World Alzheimer Report 2015. The global impact of dementia. An analysis of prevalence, incidence, cost and trends. 2015."},{"issue":"2","key":"883_CR3","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/1715163517690745","volume":"150","author":"S Duong","year":"2017","unstructured":"Duong S, Patel T, Chang F. Dementia: what pharmacists need to know. Can Pharm J (Ott). 2017;150(2):118\u201329.","journal-title":"Can Pharm J (Ott)."},{"key":"883_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fneur.2012.00073","volume":"3","author":"J Cerejeira","year":"2012","unstructured":"Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol. 2012;3:73.","journal-title":"Front Neurol"},{"issue":"3","key":"883_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1176\/jnp.3.3.243","volume":"3","author":"RS Marin","year":"1991","unstructured":"Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991;3(3):243\u201354.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"1","key":"883_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1136\/jnnp.2005.069575","volume":"77","author":"SE Starkstein","year":"2006","unstructured":"Starkstein SE, Jorge R, Mizrahi R, Robinson RG. A prospective longitudinal study of apathy in Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2006;77(1):8.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"883_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1017\/S104161029200125X","volume":"4","author":"DP Devanand","year":"1992","unstructured":"Devanand DP, Brockington CD, Moody BJ, Brown RP, Mayeux R, Endicott J, et al. Behavioral syndromes in Alzheimer\u2019s disease. Int Psychogeriatr. 1992;4(4):161\u201384.","journal-title":"Int Psychogeriatr"},{"issue":"2","key":"883_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/(SICI)1099-1166(200002)15:2<181::AID-GPS96>3.0.CO;2-I","volume":"15","author":"T Gonzales-Salvador","year":"2000","unstructured":"Gonzales-Salvador T, Lyketsos C, Baker A, Roques C, Hovanek L, Steele C, et al. Quality of life of patients with dementia in long-term care. Int J Geriatr Psychiatry. 2000;15(2):181\u20139.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"10","key":"883_CR9","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1111\/jgs.15007","volume":"65","author":"JMH Nijsten","year":"2017","unstructured":"Nijsten JMH, Leontjevas R, Pat-El R, Smalbrugge M, Koopmans R, Gerritsen DL. Apathy: risk factor for mortality in nursing home patients. J Am Geriatr Soc. 2017;65(10):2182\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"883_CR10","first-page":"120","volume":"57","author":"MA Akyol","year":"2019","unstructured":"Akyol MA, K\u00fc\u00e7\u00fckg\u00fc\u00e7l\u00fc \u00d6, Yener G. Investigation of factors affecting apathy in three major types of dementia. Noro Psikiyatr Ars. 2019;57(2):120\u20135.","journal-title":"Noro Psikiyatr Ars."},{"issue":"1","key":"883_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13195-018-0416-5","volume":"10","author":"MH Breitve","year":"2018","unstructured":"Breitve MH, Br\u00f8nnick K, Chwiszczuk LJ, Hynninen MJ, Aarsland D, Rongve A. Apathy is associated with faster global cognitive decline and early nursing home admission in dementia with Lewy bodies. Alzheimers Res Ther. 2018;10(1):83.","journal-title":"Alzheimers Res Ther."},{"issue":"2","key":"883_CR12","first-page":"253","volume":"69","author":"AB Bonfanti","year":"2009","unstructured":"Bonfanti AB, Etcheverry JL, Persi GG, Zezza H, Starkstein S, Gatto EM. Apathy in Parkinson\u2019s disease. Impairment in quality of life. Medicina (B Aires). 2009;69(2):253\u20138.","journal-title":"Medicina (B Aires)"},{"key":"883_CR13","doi-asserted-by":"publisher","first-page":"431","DOI":"10.4172\/2161-0460.1000431","volume":"8","author":"MBR Camacho","year":"2018","unstructured":"Camacho MBR, Mason SL. Apathy in Huntington\u2019s disease: a review of the current conceptualization. J Alzheimers Dis Parkinsonism. 2018;8:431.","journal-title":"J Alzheimers Dis Parkinsonism."},{"key":"883_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.eurpsy.2018.07.008","volume":"54","author":"P Robert","year":"2018","unstructured":"Robert P, Lanct\u00f4t KL, Ag\u00fcera-Ortiz L, Aalten P, Bremond F, Defrancesco M, et al. Is it time to revise the diagnostic criteria for apathy in brain disorders? The 2018 international consensus group. Eur Psychiatry. 2018;54:71\u20136.","journal-title":"Eur Psychiatry"},{"key":"883_CR15","doi-asserted-by":"publisher","unstructured":"Miller DS, Robert P, Ereshefsky L, Adler L, Bateman D, Cummings J, et al. Diagnostic criteria for apathy in neurocognitive disorders. Alzheimers Dement. 2021. https:\/\/doi.org\/10.1002\/alz.12358.","DOI":"10.1002\/alz.12358"},{"key":"883_CR16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.neuropsychologia.2017.07.003","volume":"118","author":"C Le Heron","year":"2018","unstructured":"Le Heron C, Apps MAJ, Husain M. The anatomy of apathy: a neurocognitive framework for amotivated behaviour. Neuropsychologia. 2018;118:54\u201367.","journal-title":"Neuropsychologia"},{"issue":"3","key":"883_CR17","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/jnnp-2018-318265","volume":"90","author":"C Le Heron","year":"2019","unstructured":"Le Heron C, Holroyd CB, Salamone J, Husain M. Brain mechanisms underlying apathy. J Neurol Neurosurg Psychiatry. 2019;90(3):302\u201312.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"883_CR18","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1755-5949.2010.00161.x","volume":"17","author":"RA Mitchell","year":"2011","unstructured":"Mitchell RA, Herrmann N, Lanct\u00f4t KL. The role of dopamine in symptoms and treatment of apathy in Alzheimer\u2019s disease. CNS Neurosci Ther. 2011;17(5):411\u201327.","journal-title":"CNS Neurosci Ther"},{"issue":"7","key":"883_CR19","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/JGP.0b013e31822be242","volume":"20","author":"H Brodaty","year":"2012","unstructured":"Brodaty H, Burns K. Nonpharmacological management of apathy in dementia: a systematic review. Am J Geriatr Psychiatry. 2012;20(7):549\u201364.","journal-title":"Am J Geriatr Psychiatry"},{"key":"883_CR20","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JACSJ Sterne","year":"2019","unstructured":"Sterne JACSJ, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"883_CR21","doi-asserted-by":"publisher","first-page":"9730467","DOI":"10.1155\/2016\/9730467","volume":"2016","author":"H Ju\u00e1rez Olgu\u00edn","year":"2016","unstructured":"Ju\u00e1rez Olgu\u00edn H, Calder\u00f3n Guzm\u00e1n D, Hern\u00e1ndez Garc\u00eda E, Barrag\u00e1n MG. The role of dopamine and its dysfunction as a consequence of oxidative stress. Oxid Med Cell Longev. 2016;2016:9730467.","journal-title":"Oxid Med Cell Longev"},{"key":"883_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3389\/fnagi.2019.00175","volume":"11","author":"X Pan","year":"2019","unstructured":"Pan X, Kaminga AC, Wen SW, Wu X, Acheampong K, Liu A. Dopamine and dopamine receptors in Alzheimer\u2019s disease: a systematic review and network meta-analysis. Front Aging Neurosci. 2019;11:175.","journal-title":"Front Aging Neurosci."},{"issue":"6","key":"883_CR23","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1093\/brain\/awv104","volume":"138","author":"J Gratwicke","year":"2015","unstructured":"Gratwicke J, Jahanshahi M, Foltynie T. Parkinson\u2019s disease dementia: a neural networks perspective. Brain. 2015;138(6):1454\u201376.","journal-title":"Brain"},{"issue":"3","key":"883_CR24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1515\/revneuro-2013-0004","volume":"24","author":"NS Narayanan","year":"2013","unstructured":"Narayanan NS, Rodnitzky RL, Uc EY. Prefrontal dopamine signaling and cognitive symptoms of Parkinson\u2019s disease. Rev Neurosci. 2013;24(3):267\u201378.","journal-title":"Rev Neurosci"},{"issue":"3","key":"883_CR25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/1467-9450.00238","volume":"42","author":"L B\u00e4ckman","year":"2001","unstructured":"B\u00e4ckman L, Farde L. Dopamine and cognitive functioning: Brain imaging findings in Huntington\u2019s disease and normal aging. Scand J Psychol. 2001;42(3):287\u201396.","journal-title":"Scand J Psychol"},{"issue":"5","key":"883_CR26","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1093\/brain\/awx327","volume":"141","author":"AG Murley","year":"2018","unstructured":"Murley AG, Rowe JB. Neurotransmitter deficits from frontotemporal lobar degeneration. Brain. 2018;141(5):1263\u201385.","journal-title":"Brain"},{"issue":"Pt 8","key":"883_CR27","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/brain\/122.8.1449","volume":"122","author":"MA Piggott","year":"1999","unstructured":"Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer\u2019s and Parkinson\u2019s diseases: rostrocaudal distribution. Brain. 1999;122(Pt 8):1449\u201368.","journal-title":"Brain"},{"issue":"Suppl 1","key":"883_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1017\/S1041610203009013","volume":"15","author":"JA Court","year":"2003","unstructured":"Court JA, Perry EK. Neurotransmitter abnormalities in vascular dementia. Int Psychogeriatr. 2003;15(Suppl 1):81\u20137.","journal-title":"Int Psychogeriatr"},{"issue":"3","key":"883_CR29","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/JCP.0b013e318172b479","volume":"28","author":"N Herrmann","year":"2008","unstructured":"Herrmann N, Rothenburg LS, Black SE, Ryan M, Liu BA, Busto UE, et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. J Clin Psychopharmacol. 2008;28(3):296\u2013301.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"883_CR30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1176\/appi.ajp.2017.17030316","volume":"175","author":"PR Padala","year":"2018","unstructured":"Padala PR, Padala KP, Lensing SY, Ramirez D, Monga V, Bopp MM, et al. Methylphenidate for apathy in community-dwelling older veterans with mild Alzheimer\u2019s disease: a double-blind, randomized placebo-controlled trial. Am J Psychiatry. 2018;175(2):159\u201368.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"883_CR31","doi-asserted-by":"publisher","first-page":"810","DOI":"10.4088\/JCP.12m08099","volume":"74","author":"PB Rosenberg","year":"2013","unstructured":"Rosenberg PB, Lanct\u00f4t KL, Drye LT, Herrmann N, Scherer RW, Bachman DL, et al. Safety and efficacy of methylphenidate for apathy in Alzheimer\u2019s disease: a randomized, placebo-controlled trial. J Clin Psychiatry. 2013;74(8):810\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"883_CR32","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1001\/jamaneurol.2021.3356","volume":"78","author":"J Mintzer","year":"2021","unstructured":"Mintzer J, Lanct\u00f4t KL, Scherer RW, Rosenberg PB, Herrmann N, van Dyck CH, et al. Effect of methylphenidate on apathy in patients with Alzheimer disease: the ADMET 2 randomized clinical trial. JAMA Neurol. 2021;78(11):1324\u20131332.","journal-title":"JAMA Neurol."},{"issue":"6","key":"883_CR33","doi-asserted-by":"publisher","first-page":"796","DOI":"10.4088\/JCP.10m06708","volume":"73","author":"LL Frakey","year":"2012","unstructured":"Frakey LL, Salloway S, Buelow M, Malloy P. A randomized, double-blind, placebo-controlled trial of modafinil for the treatment of apathy in individuals with mild-to-moderate Alzheimer\u2019s disease. J Clin Psychiatry. 2012;73(6):796\u2013801.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"883_CR34","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.3233\/JAD-161309","volume":"58","author":"S Nave","year":"2017","unstructured":"Nave S, Doody RS, Boada M, Grimmer T, Savola J-M, Delmar P, et al. Sembragiline in moderate Alzheimer\u2019s disease: results of a randomized, double-blind, placebo-controlled phase II Trial (MAyflOwer RoAD). J Alzheimers Dis. 2017;58(4):1217\u201328.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"883_CR35","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1176\/appi.ajp.159.3.460","volume":"159","author":"BG Pollock","year":"2002","unstructured":"Pollock BG, Mulsant BH, Rosen J, Sweet RA, Mazumdar S, Bharucha A, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry. 2002;159(3):460\u20135.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"883_CR36","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/01.jcp.0000178415.22309.8f","volume":"25","author":"P De Deyn","year":"2005","unstructured":"De Deyn P, Jeste DV, Swanink R, Kostic D, Breder C, Carson WH, et al. Aripiprazole for the treatment of psychosis in patients with Alzheimer\u2019s disease: a randomized, placebo-controlled study. J Clin Psychopharmacol. 2005;25(5):463\u20137.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"883_CR37","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/gps.1032","volume":"19","author":"PP De Deyn","year":"2004","unstructured":"De Deyn PP, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 2004;19(2):115\u201326.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"6","key":"883_CR38","first-page":"18","volume":"7","author":"J Yanofski","year":"2010","unstructured":"Yanofski J. The dopamine dilemma: using stimulants and antipsychotics concurrently. Psychiatry (Edgmont). 2010;7(6):18\u201323.","journal-title":"Psychiatry (Edgmont)"},{"issue":"7","key":"883_CR39","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S1474-4422(12)70106-0","volume":"11","author":"C Moreau","year":"2012","unstructured":"Moreau C, Delval A, Defebvre L, Dujardin K, Duhamel A, Petyt G, et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson\u2019s disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol. 2012;11(7):589\u201396.","journal-title":"Lancet Neurol"},{"key":"883_CR40","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12883-016-0610-7","volume":"16","author":"RA Hauser","year":"2016","unstructured":"Hauser RA, Slawek J, Barone P, Dohin E, Surmann E, Asgharnejad M, et al. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson\u2019s disease. BMC Neurol. 2016;16:90.","journal-title":"BMC Neurol"},{"issue":"1","key":"883_CR41","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41531-020-00142-x","volume":"6","author":"A Castrioto","year":"2020","unstructured":"Castrioto A, Thobois S, Anheim M, Quesada JL, Lhomm\u00e9e E, Klinger H, et al. A randomized controlled double-blind study of rotigotine on neuropsychiatric symptoms in de novo PD. NPJ Parkinsons Dis. 2020;6(1):41.","journal-title":"NPJ Parkinsons Dis."},{"issue":"8","key":"883_CR42","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1111\/ene.12724","volume":"22","author":"P Barone","year":"2015","unstructured":"Barone P, Santangelo G, Morgante L, Onofrj M, Meco G, Abbruzzese G, et al. A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson\u2019s disease patients. Eur J Neurol. 2015;22(8):1184\u201391.","journal-title":"Eur J Neurol"},{"issue":"1","key":"883_CR43","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13063-017-2406-5","volume":"19","author":"RW Scherer","year":"2018","unstructured":"Scherer RW, Drye L, Mintzer J, Lanct\u00f4t K, Rosenberg P, Herrmann N, et al. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial. Trials. 2018;19(1):46.","journal-title":"Trials"},{"key":"883_CR44","unstructured":"Aripiprazole in the treatment of patients with psychosis associated with dementia of Alzheimer's type. https:\/\/ClinicalTrials.gov\/show\/NCT01438060."},{"issue":"5","key":"883_CR45","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1136\/jnnp.2006.100016","volume":"78","author":"D Devos","year":"2007","unstructured":"Devos D, Krystkowiak P, Clement F, Dujardin K, Cottencin O, Waucquier N, et al. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2007;78(5):470\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"883_CR46","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2174\/1570159X13666150716165726","volume":"14","author":"TH Ferreira-Vieira","year":"2016","unstructured":"Ferreira-Vieira TH, Guimaraes IM, Silva FR, Ribeiro FM. Alzheimer\u2019s disease: targeting the cholinergic system. Curr Neuropharmacol. 2016;14(1):101\u201315.","journal-title":"Curr Neuropharmacol"},{"issue":"11","key":"883_CR47","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1586\/14737175.8.11.1703","volume":"8","author":"EJ Mufson","year":"2008","unstructured":"Mufson EJ, Counts SE, Perez SE, Ginsberg SD. Cholinergic system during the progression of Alzheimer\u2019s disease: therapeutic implications. Expert Rev Neurother. 2008;8(11):1703\u201318.","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"883_CR48","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.bbr.2009.12.048","volume":"221","author":"NI Bohnen","year":"2011","unstructured":"Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav Brain Res. 2011;221(2):564\u201373.","journal-title":"Behav Brain Res"},{"issue":"9","key":"883_CR49","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s11910-013-0377-9","volume":"13","author":"MLTM M\u00fcller","year":"2013","unstructured":"M\u00fcller MLTM, Bohnen NI. Cholinergic dysfunction in Parkinson\u2019s disease. Curr Neurol Neurosci Rep. 2013;13(9):377.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"883_CR50","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3233\/JHD-160200","volume":"5","author":"GX D\u2019Souza","year":"2016","unstructured":"D\u2019Souza GX, Waldvogel HJ. Targeting the cholinergic system to develop a novel therapy for Huntington\u2019s disease. J Huntington\u2019s Dis. 2016;5:333\u201342.","journal-title":"J Huntington's Dis."},{"issue":"2","key":"883_CR51","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/00002093-199307020-00002","volume":"7","author":"EK Perry","year":"1993","unstructured":"Perry EK, Irving D, Kerwin JM, McKeith IG, Thompson P, Collerton D, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson\u2019s and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord. 1993;7(2):69\u201379.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"6","key":"883_CR52","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/00019442-200506000-00012","volume":"13","author":"N Herrmann","year":"2005","unstructured":"Herrmann N, Rabheru K, Wang J, Binder C. Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials. Am J Geriatr Psychiatry. 2005;13(6):527\u201334.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"3","key":"883_CR53","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1176\/appi.ajp.161.3.532","volume":"161","author":"JL Cummings","year":"2004","unstructured":"Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer\u2019s disease. Am J Psychiatry. 2004;161(3):532\u20138.","journal-title":"Am J Psychiatry"},{"issue":"Suppl 2","key":"883_CR54","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000051193","volume":"9","author":"D Kaufer","year":"1998","unstructured":"Kaufer D. Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer\u2019s disease. Dement Geriatr Cogn Disord. 1998;9(Suppl 2):8\u201314.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"5","key":"883_CR55","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1212\/WNL.50.5.1222","volume":"50","author":"JC Morris","year":"1998","unstructured":"Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer\u2019s disease. Neurology. 1998;50(5):1222\u201330.","journal-title":"Neurology"},{"issue":"11","key":"883_CR56","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/(SICI)1099-1166(199911)14:11<973::AID-GPS58>3.0.CO;2-U","volume":"14","author":"B Dubois","year":"1999","unstructured":"Dubois B, McKeith I, Orgogozo JM, Collins O, Meulien D. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer\u2019s disease: the MALT study. Int J Geriatr Psychiatry. 1999;14(11):973\u201382.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"5","key":"883_CR57","doi-asserted-by":"publisher","first-page":"318","DOI":"10.4088\/JCP.v60n0510","volume":"60","author":"MA Raskind","year":"1999","unstructured":"Raskind MA, Cyrus PA, Ruzicka BB, Gulanski BI. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer\u2019s disease patients. Metrifonate Study Group. J Clin Psychiatry. 1999;60(5):318\u201325.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"883_CR58","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1177\/089198870101400211","volume":"14","author":"JL Cummings","year":"2001","unstructured":"Cummings JL, Nadel A, Masterman D, Cyrus PA. Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer\u2019s disease. J Geriatr Psychiatry Neurol. 2001;14(2):101\u20138.","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"12","key":"883_CR59","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1111\/j.1532-5415.2001.49266.x","volume":"49","author":"PN Tariot","year":"2001","unstructured":"Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer\u2019s disease in the nursing home setting. J Am Geriatr Soc. 2001;49(12):1590\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"883_CR60","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1017\/S104161020200858X","volume":"14","author":"S Gauthier","year":"2002","unstructured":"Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, Subbiah P, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer\u2019s disease. Int Psychogeriatr. 2002;14(4):389\u2013404.","journal-title":"Int Psychogeriatr"},{"issue":"6","key":"883_CR61","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1185\/030079902125001029","volume":"18","author":"S Gauthier","year":"2002","unstructured":"Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer\u2019s disease. Curr Med Res Opin. 2002;18(6):347\u201354.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"883_CR62","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1212\/01.WNL.0000129990.32253.7B","volume":"63","author":"C Holmes","year":"2004","unstructured":"Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology. 2004;63(2):214\u20139.","journal-title":"Neurology"},{"issue":"6","key":"883_CR63","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/gps.1325","volume":"20","author":"H Feldman","year":"2005","unstructured":"Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, et al. Efficacy and safety of donepezil in patients with more severe Alzheimer\u2019s disease: a subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry. 2005;20(6):559\u201369.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"12","key":"883_CR64","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1001\/archneur.61.12.1852","volume":"61","author":"B Seltzer","year":"2004","unstructured":"Seltzer B, Zolnouni P, Nunez M, Goldman R, Kumar D, Ieni J, et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol. 2004;61(12):1852\u20136.","journal-title":"Arch Neurol"},{"issue":"2","key":"883_CR65","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3233\/JAD-141983","volume":"48","author":"R Rea","year":"2015","unstructured":"Rea R, Carotenuto A, Traini E, Fasanaro AM, Manzo V, Amenta F. Apathy treatment in Alzheimer\u2019s disease: interim results of the ASCOMALVA trial. J Alzheimers Dis. 2015;48(2):377\u201383.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"883_CR66","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/hup.470060205","volume":"6","author":"A \u00c5hlin","year":"1991","unstructured":"\u00c5hlin A, Nyb\u00e4ck H, Junthe T, \u00d6hman G, Nordgren I. Tetrahydroaminoacridine in Alzheimer\u2019s dementia: clinical and biochemical results of a double-blind crossover trial. Hum Psychopharmacol Clin Exp. 1991;6(2):109\u201318.","journal-title":"Hum Psychopharmacol Clin Exp"},{"issue":"6","key":"883_CR67","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1136\/jnnp-2013-306439","volume":"85","author":"D Devos","year":"2014","unstructured":"Devos D, Moreau C, Malt\u00eate D, Lefaucheur R, Kreisler A, Eusebio A, et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson\u2019s disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry. 2014;85(6):668\u201374.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9247","key":"883_CR68","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(00)03399-7","volume":"356","author":"I McKeith","year":"2000","unstructured":"McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356(9247):2031\u20136.","journal-title":"Lancet"},{"issue":"9314","key":"883_CR69","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","volume":"359","author":"T Erkinjuntti","year":"2002","unstructured":"Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer\u2019s disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359(9314):1283\u201390.","journal-title":"Lancet"},{"issue":"2","key":"883_CR70","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3233\/JAD-160675","volume":"56","author":"A Carotenuto","year":"2017","unstructured":"Carotenuto A, Rea R, Traini E, Fasanaro AM, Ricci G, Manzo V, et al. The effect of the association between donepezil and choline alphoscerate on behavioral disturbances in Alzheimer\u2019s disease: interim results of the ASCOMALVA trial. J Alzheimers Dis. 2017;56(2):805\u201315.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"883_CR71","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1515\/tnsci-2016-0007","volume":"7","author":"D \u0160vob \u0160trac","year":"2016","unstructured":"\u0160vob \u0160trac D, Pivac N, M\u00fcck-\u0160eler D. The serotonergic system and cognitive function. Transl Neurosci. 2016;7(1):35\u201349.","journal-title":"Transl Neurosci"},{"key":"883_CR72","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.pneurobio.2016.04.001","volume":"151","author":"G \u0160imi\u0107","year":"2017","unstructured":"\u0160imi\u0107 G, Babi\u0107 Leko M, Wray S, Harrington CR, Delalle I, Jovanov-Milo\u0161evi\u0107 N, et al. Monoaminergic neuropathology in Alzheimer\u2019s disease. Prog Neurobiol. 2017;151:101\u201338.","journal-title":"Prog Neurobiol"},{"issue":"2","key":"883_CR73","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.pneurobio.2011.08.004","volume":"95","author":"P Huot","year":"2011","unstructured":"Huot P, Fox SH, Brotchie JM. The serotonergic system in Parkinson\u2019s disease. Prog Neurobiol. 2011;95(2):163\u2013212.","journal-title":"Prog Neurobiol"},{"key":"883_CR74","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fnbeh.2014.00135","volume":"8","author":"P Pla","year":"2014","unstructured":"Pla P, Orvoen S, Saudou F, David DJ, Humbert S. Mood disorders in Huntington\u2019s disease: from behavior to cellular and molecular mechanisms. Front Behav Neurosci. 2014;8:135.","journal-title":"Front Behav Neurosci"},{"key":"883_CR75","doi-asserted-by":"publisher","first-page":"102062","DOI":"10.1016\/j.nicl.2019.102062","volume":"25","author":"JJ van der Zande","year":"2020","unstructured":"van der Zande JJ, Joling M, Happach IG, Vriend C, Scheltens P, Booij J, et al. Serotonergic deficits in dementia with Lewy bodies with concomitant Alzheimer\u2019s disease pathology: an (123)I-FP-CIT SPECT study. Neuroimage Clin. 2020;25:102062.","journal-title":"Neuroimage Clin."},{"issue":"6","key":"883_CR76","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1001\/archpsyc.1989.01810060064010","volume":"46","author":"BA Lawlor","year":"1989","unstructured":"Lawlor BA, Sunderland T, Mellow AM, Hill JL, Molchan SE, Murphy DL. Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer\u2019s disease. A controlled study. Arch Gen Psychiatry. 1989;46(6):542\u20139.","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"883_CR77","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/gps.636","volume":"17","author":"KL Lanct\u00f4t","year":"2002","unstructured":"Lanct\u00f4t KL, Herrmann N, van Reekum R, Eryavec G, Naranjo CA. Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 2002;17(6):531\u201341.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"3","key":"883_CR78","first-page":"1625","volume":"17","author":"T Zhou","year":"2019","unstructured":"Zhou T, Wang J, Xin C, Kong L, Wang C. Effect of memantine combined with citalopram on cognition of BPSD and moderate Alzheimer\u2019s disease: a clinical trial. Exp Ther Med. 2019;17(3):1625\u201330.","journal-title":"Exp Ther Med"},{"issue":"5","key":"883_CR79","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1176\/appi.ajp.2016.15020248","volume":"173","author":"AK Leonpacher","year":"2016","unstructured":"Leonpacher AK, Peters ME, Drye LT, Makino KM, Newell JA, Devanand DP, et al. Effects of citalopram on neuropsychiatric symptoms in Alzheimer\u2019s dementia: evidence from the CitAD study. Am J Psychiatry. 2016;173(5):473\u201380.","journal-title":"Am J Psychiatry"},{"key":"883_CR80","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1192\/bjp.157.6.894","volume":"157","author":"AL Nyth","year":"1990","unstructured":"Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry. 1990;157:894\u2013901.","journal-title":"Br J Psychiatry"},{"issue":"4","key":"883_CR81","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1159\/000077171","volume":"17","author":"F Lebert","year":"2004","unstructured":"Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004;17(4):355\u20139.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"883_CR82","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3389\/fnmol.2019.00334","volume":"12","author":"Y Ranjbar-Slamloo","year":"2020","unstructured":"Ranjbar-Slamloo Y, Fazlali Z. Dopamine and noradrenaline in the brain; overlapping or dissociate functions? Front Mol Neurosci. 2020;12:334.","journal-title":"Front Mol Neurosci"},{"key":"883_CR83","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.brainres.2018.01.001","volume":"1702","author":"M Gannon","year":"2019","unstructured":"Gannon M, Wang Q. Complex noradrenergic dysfunction in Alzheimer\u2019s disease: low norepinephrine input is not always to blame. Brain Res. 2019;1702:12\u20136.","journal-title":"Brain Res"},{"key":"883_CR84","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3389\/fphar.2020.00435","volume":"11","author":"E Paredes-Rodriguez","year":"2020","unstructured":"Paredes-Rodriguez E, Vegas-Suarez S, Morera-Herreras T, De Deurwaerdere P, Miguelez C. The noradrenergic system in Parkinson\u2019s disease. Front Pharmacol. 2020;11:435.","journal-title":"Front Pharmacol"},{"issue":"1","key":"883_CR85","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/brain\/103.1.179","volume":"103","author":"EGS Spokes","year":"1980","unstructured":"Spokes EGS. Neurochemical alterations in Huntington\u2019s chorea: a study of post-mortem brain tissue. Brain. 1980;103(1):179\u2013210.","journal-title":"Brain"},{"issue":"2","key":"883_CR86","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1523\/JNEUROSCI.4265-05.2006","volume":"26","author":"P Szot","year":"2006","unstructured":"Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA. Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer\u2019s disease and dementia with Lewy bodies. J Neurosci. 2006;26(2):467\u201378.","journal-title":"J Neurosci"},{"issue":"1","key":"883_CR87","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jagp.2020.04.026","volume":"29","author":"CH van Dyck","year":"2021","unstructured":"van Dyck CH, Arnsten AFT, Padala PR, Brawman-Mintzer O, Lerner AJ, Porsteinsson AP, et al. Neurobiologic rationale for treatment of apathy in alzheimer\u2019s disease with methylphenidate. Am J Geriatr Psychiatry. 2021;29(1):51\u201362.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"5","key":"883_CR88","doi-asserted-by":"publisher","first-page":"e206027","DOI":"10.1001\/jamanetworkopen.2020.6027","volume":"3","author":"F Maier","year":"2020","unstructured":"Maier F, Spottke A, Bach JP, Bartels C, Buerger K, Dodel R, et al. Bupropion for the treatment of apathy in Alzheimer disease: a randomized clinical trial. JAMA Netw Open. 2020;3(5):e206027.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"883_CR89","doi-asserted-by":"publisher","first-page":"e0173872","DOI":"10.1371\/journal.pone.0173872","volume":"12","author":"H Gelderblom","year":"2017","unstructured":"Gelderblom H, W\u00fcstenberg T, McLean T, M\u00fctze L, Fischer W, Saft C, et al. Bupropion for the treatment of apathy in Huntington\u2019s disease: a multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial. PLoS ONE. 2017;12(3):e0173872.","journal-title":"PLoS ONE"},{"issue":"2","key":"883_CR90","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11011-014-9560-1","volume":"30","author":"C Wu","year":"2015","unstructured":"Wu C, Sun D. GABA receptors in brain development, function, and injury. Metab Brain Dis. 2015;30(2):367\u201379.","journal-title":"Metab Brain Dis"},{"key":"883_CR91","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/fnagi.2016.00031","volume":"8","author":"Y Li","year":"2016","unstructured":"Li Y, Sun H, Chen Z, Xu H, Bu G, Zheng H. Implications of GABAergic neurotransmission in Alzheimer\u2019s disease. Front Aging Neurosci. 2016;8:31.","journal-title":"Front Aging Neurosci."},{"key":"883_CR92","first-page":"427","volume":"40","author":"PJ de Jong","year":"1984","unstructured":"de Jong PJ, Lakke JP, Teelken AW. CSF GABA levels in Parkinson\u2019s disease. Adv Neurol. 1984;40:427\u201330.","journal-title":"Adv Neurol"},{"issue":"6","key":"883_CR93","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/j.1600-0404.1992.tb06042.x","volume":"85","author":"P Tosca","year":"1992","unstructured":"Tosca P, Canevari L, Di Paolo E, Ferrari R, Verz\u00e9 S, Zerbi F, et al. Glutamate and GABA levels in CSF from patients affected by dementia and olivo-ponto-cerebellar atrophy. Acta Neurol Scand. 1992;85(6):430\u20135.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"883_CR94","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0304-3940(90)90501-Y","volume":"113","author":"GP Reynolds","year":"1990","unstructured":"Reynolds GP, Pearson SJ, Heathfield KWG. Dementia in Huntington\u2019s disease is associated with neurochemical deficits in the caudate nucleus, not the cerebral cortex. Neurosci Lett. 1990;113(1):95\u2013100.","journal-title":"Neurosci Lett"},{"issue":"1","key":"883_CR95","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1212\/01.wnl.0000191304.55196.4d","volume":"66","author":"ED Huey","year":"2006","unstructured":"Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology. 2006;66(1):17\u201322.","journal-title":"Neurology"},{"issue":"1","key":"883_CR96","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1017\/S1041610206003899","volume":"19","author":"KL Lanct\u00f4t","year":"2007","unstructured":"Lanct\u00f4t KL, Herrmann N, Rothenburg L, Eryavec G. Behavioral correlates of GABAergic disruption in Alzheimer\u2019s disease. Int Psychogeriatr. 2007;19(1):151\u20138.","journal-title":"Int Psychogeriatr"},{"issue":"6","key":"883_CR97","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/gps.653","volume":"17","author":"RC Sival","year":"2002","unstructured":"Sival RC, Haffmans PM, Jansen PA, Duursma SA, Eikelenboom P. Sodium valproate in the treatment of aggressive behavior in patients with dementia\u2014a randomized placebo controlled clinical trial. Int J Geriatr Psychiatry. 2002;17(6):579\u201385.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"8","key":"883_CR98","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00702-014-1180-8","volume":"121","author":"Y Zhou","year":"2014","unstructured":"Zhou Y, Danbolt NC. Glutamate as a neurotransmitter in the healthy brain. J Neural Transm (Vienna). 2014;121(8):799\u2013817.","journal-title":"J Neural Transm (Vienna)"},{"key":"883_CR99","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3233\/JAD-160763","volume":"57","author":"R Wang","year":"2017","unstructured":"Wang R, Reddy PH. Role of glutamate and NMDA receptors in Alzheimer\u2019s disease. J Alzheimers Dis. 2017;57:1041\u20138.","journal-title":"J Alzheimers Dis"},{"key":"883_CR100","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fpsyt.2018.00561","volume":"9","author":"C Madeira","year":"2018","unstructured":"Madeira C, Vargas-Lopes C, Brand\u00e3o CO, Reis T, Laks J, Panizzutti R, et al. Elevated glutamate and glutamine levels in the cerebrospinal fluid of patients with probable Alzheimer\u2019s disease and depression. Front Psychiatry. 2018;9:561.","journal-title":"Front Psychiatry."},{"issue":"3","key":"883_CR101","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jphs.2020.07.011","volume":"144","author":"L Iovino","year":"2020","unstructured":"Iovino L, Tremblay ME, Civiero L. Glutamate-induced excitotoxicity in Parkinson\u2019s disease: the role of glial cells. J Pharmacol Sci. 2020;144(3):151\u201364.","journal-title":"J Pharmacol Sci"},{"issue":"3","key":"883_CR102","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.nbd.2005.05.001","volume":"20","author":"JL Albasanz","year":"2005","unstructured":"Albasanz JL, Dalf\u00f3 E, Ferrer I, Mart\u00edn M. Impaired metabotropic glutamate receptor\/phospholipase C signaling pathway in the cerebral cortex in Alzheimer\u2019s disease and dementia with Lewy bodies correlates with stage of Alzheimer\u2019s-disease-related changes. Neurobiol Dis. 2005;20(3):685\u201393.","journal-title":"Neurobiol Dis"},{"issue":"9","key":"883_CR103","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/gps.4074","volume":"29","author":"T Araki","year":"2014","unstructured":"Araki T, Wake R, Miyaoka T, Kawakami K, Nagahama M, Furuya M, et al. The effects of combine treatment of memantine and donepezil on Alzheimer\u2019s disease patients and its relationship with cerebral blood flow in the prefrontal area. Int J Geriatr Psychiatry. 2014;29(9):881\u20139.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"5","key":"883_CR104","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/gps.1341","volume":"20","author":"S Gauthier","year":"2005","unstructured":"Gauthier S, Wirth Y, M\u00f6bius HJ. Effects of memantine on behavioural symptoms in Alzheimer\u2019s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry. 2005;20(5):459\u201364.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"14","key":"883_CR105","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMoa013128","volume":"348","author":"B Reisberg","year":"2003","unstructured":"Reisberg B, Doody R, St\u00f6ffler A, Schmitt F, Ferris S, M\u00f6bius HJ. Memantine in moderate-to-severe Alzheimer\u2019s disease. N Engl J Med. 2003;348(14):1333\u201341.","journal-title":"N Engl J Med"},{"issue":"3","key":"883_CR106","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jama.291.3.317","volume":"291","author":"PN Tariot","year":"2004","unstructured":"Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317\u201324.","journal-title":"JAMA"},{"issue":"2","key":"883_CR107","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0","volume":"14","author":"B Winblad","year":"1999","unstructured":"Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999;14(2):135\u201346.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"3","key":"883_CR108","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1152\/physrev.00043.2007","volume":"88","author":"HL Haas","year":"2008","unstructured":"Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. Physiol Rev. 2008;88(3):1183\u2013241.","journal-title":"Physiol Rev"},{"issue":"1","key":"883_CR109","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.smrv.2010.06.004","volume":"15","author":"MM Thakkar","year":"2011","unstructured":"Thakkar MM. Histamine in the regulation of wakefulness. Sleep Med Rev. 2011;15(1):65\u201374.","journal-title":"Sleep Med Rev"},{"key":"883_CR110","doi-asserted-by":"publisher","first-page":"937148","DOI":"10.1155\/2015\/937148","volume":"2015","author":"JC Sedeyn","year":"2015","unstructured":"Sedeyn JC, Wu H, Hobbs RD, Levin EC, Nagele RG, Venkataraman V. Histamine induces Alzheimer\u2019s disease-like blood brain barrier breach and local cellular responses in mouse brain organotypic cultures. BioMed Res Int. 2015;2015:937148.","journal-title":"BioMed Res Int"},{"key":"883_CR111","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.neuropharm.2015.05.007","volume":"106","author":"A Zlomuzica","year":"2016","unstructured":"Zlomuzica A, Dere D, Binder S, De Souza Silva MA, Huston JP, Dere E. Neuronal histamine and cognitive symptoms in Alzheimer\u2019s disease. Neuropharmacology. 2016;106:135\u201345.","journal-title":"Neuropharmacology"},{"issue":"5","key":"883_CR112","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1046\/j.1471-4159.2002.00871.x","volume":"81","author":"JO Rinne","year":"2002","unstructured":"Rinne JO, Anichtchik OV, Eriksson KS, Kaslin J, Tuomisto L, Kalimo H, et al. Increased brain histamine levels in Parkinson\u2019s disease but not in multiple system atrophy. J Neurochem. 2002;81(5):954\u201360.","journal-title":"J Neurochem"},{"issue":"4","key":"883_CR113","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.1750-3639.2010.00465.x","volume":"21","author":"DJ van Wamelen","year":"2011","unstructured":"van Wamelen DJ, Shan L, Aziz NA, Anink JJ, Bao AM, Roos RA, et al. Functional increase of brain histaminergic signaling in Huntington\u2019s disease. Brain Pathol. 2011;21(4):419\u201327.","journal-title":"Brain Pathol"},{"issue":"4","key":"883_CR114","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/1533317513488925","volume":"28","author":"F Naddafi","year":"2013","unstructured":"Naddafi F, Mirshafiey A. The neglected role of histamine in Alzheimer\u2019s disease. Am J Alzheimer\u2019s Dis Other Dement. 2013;28(4):327\u201336.","journal-title":"Am J Alzheimer's Dis Other Dement."},{"issue":"8","key":"883_CR115","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1002\/mds.26287","volume":"30","author":"EE Benarroch","year":"2015","unstructured":"Benarroch EE, Schmeichel AM, Parisi JE, Low PA. Histaminergic tuberomammillary neuron loss in multiple system atrophy and dementia with Lewy bodies. Mov Disord. 2015;30(8):1133\u20139.","journal-title":"Mov Disord"},{"key":"883_CR116","first-page":"549","volume":"62","author":"A Stasiak","year":"2011","unstructured":"Stasiak A, Mussur M, Unzeta M, \u0141a\u017cewska D, Kiec-Kononowicz K, Fogel WA. The central histamine level in rat model of vascular dementia. J Physiol Pharmacol. 2011;62:549\u201358.","journal-title":"J Physiol Pharmacol"},{"issue":"8","key":"883_CR117","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.addbeh.2005.11.003","volume":"31","author":"A Verdejo-Garc\u00eda","year":"2006","unstructured":"Verdejo-Garc\u00eda A, Rivas-P\u00e9rez C, L\u00f3pez-Torrecillas F, P\u00e9rez-Garc\u00eda M. Differential impact of severity of drug use on frontal behavioral symptoms. Addict Behav. 2006;31(8):1373\u201382.","journal-title":"Addict Behav"},{"issue":"4","key":"883_CR118","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.biopsych.2008.08.012","volume":"65","author":"M Yoshizawa","year":"2009","unstructured":"Yoshizawa M, Tashiro M, Fukudo S, Yanai K, Utsumi A, Kano M, et al. Increased brain histamine H1 receptor binding in patients with anorexia nervosa. Biol Psychiatry (1969). 2009;65(4):329\u201335.","journal-title":"Biol Psychiatry (1969)."},{"issue":"1","key":"883_CR119","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ejphar.2006.11.048","volume":"558","author":"WE Horner","year":"2007","unstructured":"Horner WE, Johnson DE, Schmidt AW, Rollema H. Methylphenidate and atomoxetine increase histamine release in rat prefrontal cortex. Eur J Pharmacol. 2007;558(1):96\u20137.","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"883_CR120","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/014107680209500503","volume":"95","author":"IO Ebrahim","year":"2002","unstructured":"Ebrahim IO, Howard RS, Kopelman MD, Sharief MK, Williams AJ. The hypocretin\/orexin system. J R Soc Med. 2002;95(5):227\u201330.","journal-title":"J R Soc Med"},{"issue":"7","key":"883_CR121","doi-asserted-by":"publisher","first-page":"621","DOI":"10.30773\/pi.2020.0136","volume":"17","author":"YH Um","year":"2020","unstructured":"Um YH, Lim HK. Orexin and Alzheimer\u2019s disease: a new perspective. Psychiatry Investig. 2020;17(7):621\u20136.","journal-title":"Psychiatry Investig"},{"key":"883_CR122","doi-asserted-by":"publisher","first-page":"104754","DOI":"10.1016\/j.neuint.2020.104754","volume":"138","author":"C Liu","year":"2020","unstructured":"Liu C, Xue Y, Liu M-F, Wang Y, Chen L. Orexin and Parkinson\u2019s disease: a protective neuropeptide with therapeutic potential. Neurochem Int. 2020;138:104754.","journal-title":"Neurochem Int"},{"issue":"1","key":"883_CR123","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/hmg\/ddi004","volume":"14","author":"\u00c5 Peters\u00e9n","year":"2005","unstructured":"Peters\u00e9n \u00c5, Gil J, Maat-Schieman MLC, Bj\u00f6rkqvist M, Tanila H, Ara\u00fajo IM, et al. Orexin loss in Huntington\u2019s disease. Hum Mol Genet. 2005;14(1):39\u201347.","journal-title":"Hum Mol Genet"},{"issue":"6","key":"883_CR124","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1177\/1533317513494453","volume":"28","author":"A \u00c7oban","year":"2013","unstructured":"\u00c7oban A, Bilgi\u00e7 B, Lohmann E, K\u00fc\u00e7\u00fckali C\u0130, Benbir G, Karadeniz D, et al. Reduced orexin\u2014a levels in frontotemporal dementia: possible association with sleep disturbance. Am J Alzheimer\u2019s Dis Other Dement. 2013;28(6):606\u201311.","journal-title":"Am J Alzheimer's Dis Other Dement."},{"key":"883_CR125","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13041-015-0106-1","volume":"8","author":"J Song","year":"2015","unstructured":"Song J, Kim E, Kim C-H, Song H-T, Lee JE. The role of orexin in post-stroke inflammation, cognitive decline, and depression. Mol Brain. 2015;8:16.","journal-title":"Mol Brain"},{"issue":"11","key":"883_CR126","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/WNR.0b013e32833bfb7c","volume":"21","author":"S Lessig","year":"2010","unstructured":"Lessig S, Ubhi K, Galasko D, Adame A, Pham E, Remidios K, et al. Reduced hypocretin (orexin) levels in dementia with Lewy bodies. NeuroReport. 2010;21(11):756\u201360.","journal-title":"NeuroReport"},{"key":"883_CR127","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.neuroscience.2012.05.033","volume":"218","author":"C Nocjar","year":"2012","unstructured":"Nocjar C, Zhang J, Feng P, Panksepp J. The social defeat animal model of depression shows diminished levels of orexin in mesocortical regions of the dopamine system, and of dynorphin and orexin in the hypothalamus. Neuroscience. 2012;218:138\u201353.","journal-title":"Neuroscience"},{"issue":"6","key":"883_CR128","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.npep.2012.08.005","volume":"46","author":"P Holzer","year":"2012","unstructured":"Holzer P, Reichmann F, Farzi A, Neuropeptide Y. peptide YY and pancreatic polypeptide in the gut-brain axis. Neuropeptides. 2012;46(6):261\u201374.","journal-title":"Neuropeptides"},{"issue":"1","key":"883_CR129","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2174\/157015909787602779","volume":"7","author":"F Ferrini","year":"2009","unstructured":"Ferrini F, Salio C, Lossi L, Merighi A. Ghrelin in central neurons. Curr Neuropharmacol. 2009;7(1):37\u201349.","journal-title":"Curr Neuropharmacol"},{"key":"883_CR130","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3389\/fncel.2019.00205","volume":"13","author":"D Serrenho","year":"2019","unstructured":"Serrenho D, Santos SD, Carvalho AL. The role of ghrelin in regulating synaptic function and plasticity of feeding-associated circuits. Front Cell Neurosci. 2019;13:205.","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"883_CR131","doi-asserted-by":"publisher","first-page":"14057","DOI":"10.1038\/s41598-017-14020-9","volume":"7","author":"S Pedrini","year":"2017","unstructured":"Pedrini S, Gupta VB, Hone E, Doecke J, O\u2019Bryant S, James I, et al. A blood-based biomarker panel indicates IL-10 and IL-12\/23p40 are jointly associated as predictors of \u03b2-amyloid load in an AD cohort. Sci Rep. 2017;7(1):14057.","journal-title":"Sci Rep"},{"issue":"2","key":"883_CR132","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s12035-016-9729-1","volume":"54","author":"L Shi","year":"2017","unstructured":"Shi L, Du X, Jiang H, Xie J. Ghrelin and neurodegenerative disorders\u2014a review. Mol Neurobiol. 2017;54(2):1144\u201355.","journal-title":"Mol Neurobiol"},{"key":"883_CR133","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.3389\/fneur.2019.01155","volume":"10","author":"D Yang","year":"2019","unstructured":"Yang D, Zhao D, Ali Shah SZ, Wu W, Lai M, Zhang X, et al. The role of the gut microbiota in the pathogenesis of Parkinson\u2019s disease. Front Neurol. 2019;10:1155.","journal-title":"Front Neurol"},{"issue":"7","key":"883_CR134","doi-asserted-by":"publisher","first-page":"100120","DOI":"10.1016\/j.xcrm.2020.100120","volume":"1","author":"AKE Hornsby","year":"2020","unstructured":"Hornsby AKE, Buntwal L, Carisi MC, Santos VV, Johnston F, Roberts LD, et al. Unacylated-ghrelin impairs hippocampal neurogenesis and memory in mice and is altered in parkinson\u2019s dementia in humans. Cell Rep Med. 2020;1(7):100120.","journal-title":"Cell Rep Med."},{"issue":"10","key":"883_CR135","doi-asserted-by":"publisher","first-page":"e47240","DOI":"10.1371\/journal.pone.0047240","volume":"7","author":"W Cong","year":"2012","unstructured":"Cong W, Cai H, Wang R, Daimon CM, Maudsley S, Raber K, et al. Altered hypothalamic protein expression in a rat model of Huntington\u2019s disease. PLoS ONE. 2012;7(10):e47240.","journal-title":"PLoS ONE"},{"key":"883_CR136","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.nbd.2014.08.026","volume":"72","author":"II Stoyanova","year":"2014","unstructured":"Stoyanova II. Ghrelin: a link between ageing, metabolism and neurodegenerative disorders. Neurobiol Dis. 2014;72:72\u201383.","journal-title":"Neurobiol Dis"},{"issue":"9","key":"883_CR137","doi-asserted-by":"publisher","first-page":"7555","DOI":"10.1007\/s12035-018-0931-1","volume":"55","author":"C Yamada","year":"2018","unstructured":"Yamada C, Mogami S, Kanno H, Hattori T. Peptide YY causes apathy-like behavior via the dopamine D2 receptor in repeated water-immersed mice. Mol Neurobiol. 2018;55(9):7555\u201366.","journal-title":"Mol Neurobiol"},{"issue":"3","key":"883_CR138","doi-asserted-by":"publisher","first-page":"238","DOI":"10.2174\/157015909789152182","volume":"7","author":"TE Bjorness","year":"2009","unstructured":"Bjorness TE, Greene RW. Adenosine and sleep. Curr Neuropharmacol. 2009;7(3):238\u201345.","journal-title":"Curr Neuropharmacol"},{"key":"883_CR139","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/B978-0-12-801022-8.00012-X","volume":"119","author":"JF Chen","year":"2014","unstructured":"Chen JF. Adenosine receptor control of cognition in normal and disease. Int Rev Neurobiol. 2014;119:257\u2013307.","journal-title":"Int Rev Neurobiol"},{"issue":"3","key":"883_CR140","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2174\/157015909789152119","volume":"7","author":"R Anisur","year":"2009","unstructured":"Anisur R. The role of adenosine in Alzheimers disease. Curr Neuropharmacol. 2009;7(3):207\u201316.","journal-title":"Curr Neuropharmacol"},{"key":"883_CR141","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3389\/fnins.2017.00658","volume":"11","author":"LR Nazario","year":"2017","unstructured":"Nazario LR, da Silva RS, Bonan CD. Targeting adenosine signaling in Parkinson\u2019s disease: from pharmacological to non-pharmacological approaches. Front Neurosci. 2017;11:658.","journal-title":"Front Neurosci"},{"key":"883_CR142","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/B978-0-12-801022-8.00008-8","volume":"119","author":"S Uchida","year":"2014","unstructured":"Uchida S, Kadowaki-Horita T, Kanda T. Effects of the adenosine A2A receptor antagonist on cognitive dysfunction in Parkinson\u2019s disease. Int Rev Neurobiol. 2014;119:169\u201389.","journal-title":"Int Rev Neurobiol"},{"issue":"7","key":"883_CR143","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1096\/fj.00-0730fje","volume":"15","author":"K Varani","year":"2001","unstructured":"Varani K, Rigamonti D, Sipione S, Camurri A, Borea PA, Cattabeni F, et al. Aberrant amplification of A(2A) receptor signaling in striatal cells expressing mutant huntingtin. Faseb j. 2001;15(7):1245\u20137.","journal-title":"Faseb j"},{"issue":"1","key":"883_CR144","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.nbd.2006.01.014","volume":"23","author":"A Tarditi","year":"2006","unstructured":"Tarditi A, Camurri A, Varani K, Borea PA, Woodman B, Bates G, et al. Early and transient alteration of adenosine A2A receptor signaling in a mouse model of Huntington disease. Neurobiol Dis. 2006;23(1):44\u201353.","journal-title":"Neurobiol Dis"},{"issue":"5","key":"883_CR145","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.bbamem.2010.12.001","volume":"1808","author":"CV Gomes","year":"2011","unstructured":"Gomes CV, Kaster MP, Tom\u00e9 AR, Agostinho PM, Cunha RA. Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Biochim Biophys Acta. 2011;1808(5):1380\u201399.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"883_CR146","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/jnc.12177","volume":"125","author":"A Martire","year":"2013","unstructured":"Martire A, Pepponi R, Domenici MR, Ferrante A, Chiodi V, Popoli P. BDNF prevents NMDA-induced toxicity in models of Huntington\u2019s disease: the effects are genotype specific and adenosine A2A receptor is involved. J Neurochem. 2013;125(2):225\u201335.","journal-title":"J Neurochem"},{"key":"883_CR147","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.nbd.2014.11.004","volume":"74","author":"S Tyebji","year":"2015","unstructured":"Tyebji S, Saavedra A, Canas PM, Pliassova A, Delgado-Garc\u00eda JM, Alberch J, et al. Hyperactivation of D1 and A2A receptors contributes to cognitive dysfunction in Huntington\u2019s disease. Neurobiol Dis. 2015;74:41\u201357.","journal-title":"Neurobiol Dis"},{"issue":"11","key":"883_CR148","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1093\/brain\/awz288","volume":"142","author":"K Carvalho","year":"2019","unstructured":"Carvalho K, Faivre E, Pietrowski MJ, Marques X, Gomez-Murcia V, Deleau A, et al. Exacerbation of C1q dysregulation, synaptic loss and memory deficits in tau pathology linked to neuronal adenosine A2A receptor. Brain. 2019;142(11):3636\u201354.","journal-title":"Brain"},{"key":"883_CR149","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3233\/JAD-131652","volume":"40","author":"C Gussago","year":"2014","unstructured":"Gussago C, Arosio B, Casati M, Ferri E, Gualandris F, Tedone E, et al. Different adenosine A 2A receptor expression in peripheral cells from elderly patients with vascular dementia and Alzheimer\u2019s disease. J Alzheimers Dis. 2014;40:45\u20139.","journal-title":"J Alzheimers Dis"},{"key":"883_CR150","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3389\/fneur.2017.00089","volume":"8","author":"P Garcia-Esparcia","year":"2017","unstructured":"Garcia-Esparcia P, L\u00f3pez-Gonz\u00e1lez I, Grau-Rivera O, Garc\u00eda-Garrido MF, Konetti A, Llorens F, et al. Dementia with lewy bodies: molecular pathology in the frontal cortex in typical and rapidly progressive forms. Front Neurol. 2017;8:89.","journal-title":"Front Neurol"},{"key":"883_CR151","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jns.2018.11.005","volume":"396","author":"H Nagayama","year":"2019","unstructured":"Nagayama H, Kano O, Murakami H, Ono K, Hamada M, Toda T, et al. Effect of istradefylline on mood disorders in Parkinson\u2019s disease. J Neurol Sci. 2019;396:78\u201383.","journal-title":"J Neurol Sci"},{"key":"883_CR152","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.nbd.2017.10.014","volume":"110","author":"AG Orr","year":"2018","unstructured":"Orr AG, Lo I, Schumacher H, Ho K, Gill M, Guo W, et al. Istradefylline reduces memory deficits in aging mice with amyloid pathology. Neurobiol Dis. 2018;110:29\u201336.","journal-title":"Neurobiol Dis"},{"key":"883_CR153","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.nbd.2015.03.030","volume":"79","author":"W Li","year":"2015","unstructured":"Li W, Silva HB, Real J, Wang Y-M, Rial D, Li P, et al. Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington\u2019s disease models. Neurobiol Dis. 2015;79:70\u201380.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"883_CR154","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3233\/JAD-151113","volume":"54","author":"PB Rosenberg","year":"2016","unstructured":"Rosenberg PB, Lanct\u00f4t KL, Herrmann N, Mintzer JE, Porsteinsson AP, Sun X, et al. Changes in neuropsychiatric inventory associated with semagacestat treatment of Alzheimer\u2019s disease. J Alzheimers Dis. 2016;54(1):373\u201381.","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"883_CR155","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1017\/S1041610212002141","volume":"25","author":"PT Trzepacz","year":"2013","unstructured":"Trzepacz PT, Cummings J, Konechnik T, Forrester TD, Chang C, Dennehy EB, et al. Mibampator (LY451395) randomized clinical trial for agitation\/aggression in Alzheimer\u2019s disease. Int Psychogeriatr. 2013;25(5):707\u201319.","journal-title":"Int Psychogeriatr"},{"issue":"3\u20134","key":"883_CR156","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1159\/000355373","volume":"37","author":"SY Kim","year":"2014","unstructured":"Kim SY, Choi SH, Rollema H, Schwam EM, McRae T, Dubrava S, et al. Phase II crossover trial of varenicline in mild-to-moderate Alzheimer\u2019s disease. Dement Geriatr Cogn Disord. 2014;37(3\u20134):232\u201345.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"4","key":"883_CR157","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/0278-5846(90)90005-2","volume":"14","author":"TA Ban","year":"1990","unstructured":"Ban TA, Morey L, Aguglia E, Azzarelli O, Balsano F, Marigliano V, et al. Nimodipine in the treatment of old age dementias. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14(4):525\u201351.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"13\u201314","key":"883_CR158","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10354-007-0427-5","volume":"157","author":"A Scripnikov","year":"2007","unstructured":"Scripnikov A, Khomenko A, Napryeyenko O. Effects of Ginkgo biloba extract EGb 761 on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial. Wien Med Wochenschr. 2007;157(13\u201314):295\u2013300.","journal-title":"Wien Med Wochenschr"},{"key":"883_CR159","first-page":"209","volume":"7","author":"N Bachinskaya","year":"2011","unstructured":"Bachinskaya N, Hoerr R, Ihl R. Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761. Findings from a randomized controlled trial. Neuropsychiatr Dis Treat. 2011;7:209\u201315.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"883_CR160","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1159\/000117279","volume":"36","author":"A Bayer","year":"1996","unstructured":"Bayer A, Bokonjic R, Booya N. European pentoxifylline multi-infarct dementia study. Eur Neurol. 1996;36(5):315\u201321.","journal-title":"Eur Neurol"},{"issue":"2","key":"883_CR161","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1212\/WNL.0000000000001133","volume":"84","author":"EC Finger","year":"2015","unstructured":"Finger EC, MacKinley J, Blair M, Oliver LD, Jesso S, Tartaglia MC, et al. Oxytocin for frontotemporal dementia: a randomized dose-finding study of safety and tolerability. Neurology. 2015;84(2):174\u201381.","journal-title":"Neurology"},{"issue":"5\u20136","key":"883_CR162","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000445873","volume":"16","author":"I Callegari","year":"2016","unstructured":"Callegari I, Mattei C, Benassi F, Krueger F, Grafman J, Yaldizli \u00d6, et al. Agomelatine Improves Apathy in Frontotemporal Dementia. Neurodegener Dis. 2016;16(5\u20136):352\u20136.","journal-title":"Neurodegener Dis"},{"key":"883_CR163","doi-asserted-by":"crossref","unstructured":"Ruthirakuhan MT, Herrmann N, Abraham EH, Chan S, Lanct\u00f4t KL. Pharmacological interventions for apathy in Alzheimer's disease. Cochrane Database Syst Rev. 2018;5(5):CD012197.","DOI":"10.1002\/14651858.CD012197.pub2"},{"issue":"27","key":"883_CR164","doi-asserted-by":"publisher","first-page":"e20931-e","DOI":"10.1097\/MD.0000000000020931","volume":"99","author":"G Charach","year":"2020","unstructured":"Charach G, Karniel E, Grosskopf I, Rabinovich A, Charach L. Methylphenidate has mild hyperglycemic and hypokalemia effects and increases leukocyte and neutrophil counts. Medicine (Baltimore). 2020;99(27):e20931-e.","journal-title":"Medicine (Baltimore)"},{"key":"883_CR165","doi-asserted-by":"publisher","first-page":"i2550","DOI":"10.1136\/bmj.i2550","volume":"353","author":"J-Y Shin","year":"2016","unstructured":"Shin J-Y, Roughead EE, Park B-J, Pratt NL. Cardiovascular safety of methylphenidate among children and young people with attention-deficit\/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ. 2016;353:i2550.","journal-title":"BMJ"},{"issue":"5","key":"883_CR166","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/gps.1949","volume":"23","author":"S Gauthier","year":"2008","unstructured":"Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer\u2019s disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry. 2008;23(5):537\u201345.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"3","key":"883_CR167","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s13181-018-0669-1","volume":"14","author":"H Ohbe","year":"2018","unstructured":"Ohbe H, Jo T, Matsui H, Fushimi K, Yasunaga H. Cholinergic crisis caused by cholinesterase inhibitors: a retrospective nationwide database study. J Med Toxicol. 2018;14(3):237\u201341.","journal-title":"J Med Toxicol"},{"issue":"2","key":"883_CR168","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3233\/JAD-200133","volume":"76","author":"D Barthold","year":"2020","unstructured":"Barthold D, Joyce G, Ferido P, Drabo EF, Marcum ZA, Gray SL, et al. Pharmaceutical treatment for Alzheimer\u2019s disease and related dementias: utilization and disparities. J Alzheimer\u2019s Dis JAD. 2020;76(2):579\u201389.","journal-title":"J Alzheimer's Dis JAD."},{"issue":"5","key":"883_CR169","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/2040622316658463","volume":"7","author":"RR Tampi","year":"2016","unstructured":"Tampi RR, Tampi DJ, Balachandran S, Srinivasan S. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016;7(5):229\u201345.","journal-title":"Ther Adv Chronic Dis."},{"issue":"7","key":"883_CR170","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/jama.2014.93","volume":"311","author":"AP Porsteinsson","year":"2014","unstructured":"Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682\u201391.","journal-title":"JAMA"},{"issue":"8","key":"883_CR171","doi-asserted-by":"publisher","first-page":"e0160768-e","DOI":"10.1371\/journal.pone.0160768","volume":"11","author":"E Qirjazi","year":"2016","unstructured":"Qirjazi E, McArthur E, Nash DM, Dixon SN, Weir MA, Vasudev A, et al. Risk of ventricular arrhythmia with citalopram and escitalopram: a population-based study. PLoS ONE. 2016;11(8):e0160768-e.","journal-title":"PLoS ONE"},{"key":"883_CR172","doi-asserted-by":"publisher","first-page":"285","DOI":"10.18433\/J3Q35D","volume":"20","author":"F Chen","year":"2017","unstructured":"Chen F, Jin L, Nie Z. Safety and efficacy of rotigotine for treating Parkinson\u2019s disease: a meta-analysis of randomised controlled trials. J Pharm Pharm Sci. 2017;20:285\u201394.","journal-title":"J Pharm Pharm Sci"},{"issue":"9","key":"883_CR173","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40263-019-00661-z","volume":"33","author":"F Carbone","year":"2019","unstructured":"Carbone F, Djamshidian A, Seppi K, Poewe W. Apomorphine for parkinson\u2019s disease: efficacy and safety of current and new formulations. CNS Drugs. 2019;33(9):905\u201318.","journal-title":"CNS Drugs"},{"issue":"1","key":"883_CR174","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3233\/ADR-170026","volume":"1","author":"M Ohsawa","year":"2017","unstructured":"Ohsawa M, Tanaka Y, Ehara Y, Makita S, Onaka K. A possibility of simultaneous treatment with the multicomponent drug, Ninjin\u2019yoeito, for anorexia, apathy, and cognitive dysfunction in frail Alzheimer\u2019s disease patients: an open-label pilot study. J Alzheimers Dis Rep. 2017;1(1):229\u201335.","journal-title":"J Alzheimers Dis Rep."},{"issue":"1","key":"883_CR175","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3109\/02699059509004571","volume":"9","author":"R Van Reekum","year":"1995","unstructured":"Van Reekum R, Bayley M, Garner S, Burke IM, Fawcett S, Hart A, et al. N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury. Brain Inj. 1995;9(1):49\u201353.","journal-title":"Brain Inj"},{"issue":"5","key":"883_CR176","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/j.1532-5415.1975.tb00187.x","volume":"23","author":"JU Postma","year":"1975","unstructured":"Postma JU, Van Tilburg W. Visual hallucinations and delirium during treatment with amantadine (Symmetrel). J Am Geriatr Soc. 1975;23(5):212\u20135.","journal-title":"J Am Geriatr Soc"},{"key":"883_CR177","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.3389\/fphar.2019.01108","volume":"10","author":"CG Theleritis","year":"2019","unstructured":"Theleritis CG, Siarkos KT, Politis AM. Unmet needs in pharmacological treatment of apathy in Alzheimer\u2019s disease: a systematic review. Front Pharmacol. 2019;10:1108.","journal-title":"Front Pharmacol"},{"issue":"3","key":"883_CR178","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3233\/JAD-143084","volume":"45","author":"K Matsuzono","year":"2015","unstructured":"Matsuzono K, Hishikawa N, Ohta Y, Yamashita T, Deguchi K, Nakano Y, et al. Combination therapy of cholinesterase inhibitor (donepezil or galantamine) plus memantine in the okayama memantine study. J Alzheimers Dis. 2015;45(3):771\u201380.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"883_CR179","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jalz.2016.05.008","volume":"13","author":"KL Lanct\u00f4t","year":"2017","unstructured":"Lanct\u00f4t KL, Ag\u00fcera-Ortiz L, Brodaty H, Francis PT, Geda YE, Ismail Z, et al. Apathy associated with neurocognitive disorders: recent progress and future directions. Alzheimers Dement. 2017;13(1):84\u2013100.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"883_CR180","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3233\/JAD-180485","volume":"66","author":"D Mohammad","year":"2018","unstructured":"Mohammad D, Ellis C, Rau A, Rosenberg PB, Mintzer J, Ruthirakuhan M, et al. Psychometric properties of apathy scales in dementia: a systematic review. J Alzheimers Dis. 2018;66(3):1065\u201382.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"883_CR181","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/0891988715573534","volume":"28","author":"J Cummings","year":"2015","unstructured":"Cummings J, Friedman JH, Garibaldi G, Jones M, Macfadden W, Marsh L, et al. Apathy in neurodegenerative diseases: recommendations on the design of clinical trials. J Geriatr Psychiatry Neurol. 2015;28(3):159\u201373.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"883_CR182","unstructured":"Glenn M. The Apathy Evaluation Scale. The center for outcome measurement in brain injury. 2005. http:\/\/www.tbims.org\/combi\/aes."},{"issue":"5 Suppl 6","key":"883_CR183","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1212\/WNL.48.5_Suppl_6.10S","volume":"48","author":"JL Cummings","year":"1997","unstructured":"Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(5 Suppl 6):S10\u20136.","journal-title":"Neurology"},{"issue":"4","key":"883_CR184","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/wvn.12459","volume":"17","author":"Y Cai","year":"2020","unstructured":"Cai Y, Li L, Xu C, Wang Z. The effectiveness of non-pharmacological interventions on apathy in patients with dementia: a systematic review of systematic reviews. Worldviews Evid Based Nurs. 2020;17(4):311\u20138.","journal-title":"Worldviews Evid Based Nurs."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00883-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-021-00883-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00883-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T09:03:37Z","timestamp":1666515817000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-021-00883-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":184,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["883"],"URL":"https:\/\/doi.org\/10.1007\/s40263-021-00883-0","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]},"assertion":[{"value":"21 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used to assist with the preparation of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Krista L. Lanct\u00f4t has received grants from the Alzheimer\u2019s Association, the Alzheimer\u2019s Drug Discovery Foundation, the Canadian Institutes of Health Research, the National Institutes of Aging, and the Weston Brain Institute; consulting fees from BioXcel, Cerevel, Eisai,\u00a0GW Pharma,\u00a0ICG Pharma, Kondor Pharma,\u00a0Novo Nordisk, Otsuka, and Praxis; and stock options from Highmark Interactive outside the submitted work. Nathan Herrmann, Laiba Azhar, Raphael W. Kusumo, and Giovanni Marotta have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"The idea for the review was suggested by Nathan Herrmann. Drafts of the manuscript and literature searches were written and performed by Laiba Azhar, Nathan Herrmann, Krista L. Lanct\u00f4t, and Raphael W. Kusumo. All authors reviewed and commented on all versions of the manuscript, approved the final manuscript, and agree to be accountable for the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}